Positive Media Coverage Somewhat Unlikely to Impact Pacific Biosciences (PACB) Stock Price

News coverage about Pacific Biosciences (NASDAQ:PACB) has been trending positive this week, Accern reports. Accern identifies positive and negative news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Pacific Biosciences earned a coverage optimism score of 0.38 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 47.3004934548277 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

These are some of the news stories that may have effected Accern’s rankings:

Shares of NASDAQ:PACB traded up $0.10 during midday trading on Thursday, hitting $2.42. The company had a trading volume of 748,399 shares, compared to its average volume of 1,133,929. Pacific Biosciences has a twelve month low of $2.02 and a twelve month high of $5.70. The company has a debt-to-equity ratio of 0.16, a quick ratio of 2.74 and a current ratio of 3.55. The stock has a market cap of $292.75, a PE ratio of -2.78 and a beta of 1.61.

Pacific Biosciences (NASDAQ:PACB) last posted its quarterly earnings results on Thursday, February 1st. The biotechnology company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.20) by $0.02. The firm had revenue of $24.94 million during the quarter, compared to analysts’ expectations of $21.89 million. Pacific Biosciences had a negative return on equity of 98.98% and a negative net margin of 98.63%. The business’s revenue for the quarter was down 3.1% on a year-over-year basis. During the same quarter last year, the firm earned ($0.21) earnings per share. analysts predict that Pacific Biosciences will post -0.63 earnings per share for the current fiscal year.

A number of equities analysts have commented on PACB shares. BidaskClub cut Pacific Biosciences from a “sell” rating to a “strong sell” rating in a report on Saturday, January 13th. Zacks Investment Research cut Pacific Biosciences from a “hold” rating to a “sell” rating in a report on Tuesday, January 9th. Three research analysts have rated the stock with a sell rating, two have assigned a hold rating and one has assigned a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $6.27.

ILLEGAL ACTIVITY NOTICE: This article was first reported by BBNS and is the sole property of of BBNS. If you are viewing this article on another website, it was stolen and reposted in violation of United States and international trademark and copyright laws. The correct version of this article can be accessed at https://baseballnewssource.com/2018/04/05/pacific-biosciences-of-california-pacb-earns-news-impact-score-of-0-38/2028074.html.

Pacific Biosciences Company Profile

Pacific Biosciences of California, Inc designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company's single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes. It offers PacBio RS II and Sequel Systems that conducts, monitors, and analyzes single molecule biochemical reactions in real time.

Insider Buying and Selling by Quarter for Pacific Biosciences (NASDAQ:PACB)

Receive News & Ratings for Pacific Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacific Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

 




Latest News

Ji-Man Choi Receives Another Chance in Milwaukee
Ji-Man Choi Receives Another Chance in Milwaukee
Marlins vs Dodgers sets a 10-year record in MGM sportsbooks
Marlins vs Dodgers sets a 10-year record in MGM sportsbooks
Strikeouts Once Again Plaguing Cubs
Strikeouts Once Again Plaguing Cubs
Atlanta Braves: A Mix of Young and Old
Atlanta Braves: A Mix of Young and Old
Major League Baseball is Back and Astros Favored to Repeat
Major League Baseball is Back and Astros Favored to Repeat
Jim Kaat: Baseball Would Be Helped by Shortening Game to Seven Innings
Jim Kaat: Baseball Would Be Helped by Shortening Game to Seven Innings


Leave a Reply

 
© 2006-2018 BBNS.